• 1
    Ezekowitz JA. Anemia in patients with advanced heart failure. J Am Coll Cardiol. 2007;49(23):2301.
  • 2
    Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93(6):665671.
  • 3
    Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113(20):24542461.
  • 4
    Luthi JC, Flanders WD, Burnier M, et al. Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients. BMC Nephrol. 2006;7:3.
  • 5
    Grigorian SL, Varela RA, Garcia-Acuna JM, et al. Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. Heart. 2006;92(6):780784.
  • 6
    O’Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113(7):986994.
  • 7
    Gardner RS, McDonagh TA. The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure. Expert Rev Cardiovasc Ther. 2006;4(1):5157.
  • 8
    Ralli S, Horwich TB, Fonarow GC. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J. 2005;150(6):12201227.
  • 9
    Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110(2):149154.
  • 10
    Brucks S, Little WC, Chao T, et al. Relation of anemia to diastolic heart failure and the effect on outcome. AJC. 2004;93(8):10551057.
  • 11
    Silverberg D, Wexler D, Blum M, et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13(2):163170.
  • 12
    Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223225.
  • 13
    Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007;154(4):645.e9e15.
  • 14
    Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152(6):1096.e91096.e15.
  • 15
    Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107(2):294299.
  • 16
    Silverberg DS, Wexler D, Blum M, et al. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol. 2003;60(suppl 1):S93S102.
  • 17
    Silverberg DS, Wexler D, Blum M, et al. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J. 2003;5(5):337339.
  • 18
    Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37(7):17751780.
  • 19
    Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):16571665.
  • 20
    Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):12251227.
  • 21
    Ghali JK, Anand IS, Abraham WT, et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation. 2008;117(4):526535.
  • 22
    Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20(2):301306.
  • 23
    World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. 1968; Geneva, Switzerland: World Health Organization; 2007.
  • 24
    Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation. 1977;56(4 Pt 1):605612.
  • 25
    Katz SD. Blood volume assessment in the diagnosis and treatment of chronic heart failure. Am J Med Sci. 2007;334(1):4752.
  • 26
    Feldschuh J, Katz S. The importance of correct norms in blood volume measurement. Am J Med Sci. 2007;334(1):4146.
  • 27
    Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58(6):10721083.
  • 28
    Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102(15):17881794.
  • 29
    Gopal AS, King DL, Katz J, et al. Three-dimensional echocardiographic volume computation by polyhedral surface reconstruction: in vitro validation and comparison to magnetic resonance imaging. J Am Soc Echocardiogr. 1992;5(2):115124.
  • 30
    King DL. Three-dimensional Ultrasonic Imaging of Animal Soft Tissue. United States patent 4,100,916. 1978 Jul 18.
  • 31
    Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effect of encouragement on walking test performance. Thorax. 1984;39(11):818822.
  • 32
    Cahalin LP, Mathier MA, Semigran MJ, et al. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 1996;110(2):325332.
  • 33
    Lang CC, Karlin P, Haythe J, et al. Ease of noninvasive measurement of cardiac output coupled with peak VO2 determination at rest and during exercise in patients with heart failure. AJC. 2007;99(3):404405.
  • 34
    Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):12451255.
  • 35
    Chen CH, Fetics B, Nevo E, et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001;38(7):20282034.
  • 36
    Sunagawa K, Maughan WL, Burkhoff D, et al. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol. 1983;245(5 Pt 1):H773H780.
  • 37
    Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86(2):513521.
  • 38
    Klotz S, Hay I, Dickstein ML, et al. Single-beat estimation of end-diastolic pressure–volume relationship: a novel method with potential for noninvasive application. Am J Physiol Heart Circ Physiol. 2006;291(1):H403H412.
  • 39
    Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure–volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289(2):H501H512.
  • 40
    Suga H, Goto Y, Futaki S, et al. Systolic pressure–volume area (PVA) as the energy of contraction in Starling’s law of the heart. Heart Vessels. 1991;6(2):6570.
  • 41
    Todaka K, Wang J, Yi GH, et al. Impact of exercise training on ventricular properties in a canine model of congestive heart failure. Am J Physiol. 1997;272(3 Pt 2):H1382H1390.
  • 42
    Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226229.
  • 43
    Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965976.
  • 44
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):20852098.
  • 45
    Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):20712084.
  • 46
    Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381388.
  • 47
    Information on Erythropoiesis Stimulating Agents (ESA) (marketed as Procrit, Epogen, and Aranesp). 2007.
  • 48
    II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 suppl 3):S16S85.
  • 49
    Anemia in Heart Failure with a Normal Ejection Fraction (HFNEF). NCT00286182.
  • 50
    Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):16281637.
  • 51
    Jones M, Schenkel B, Just J. Epoetin alfa’s effect on left ventricular hypertrophy and subsequent mortality. Int J Cardiol. 2005;100(2):253265.
  • 52
    Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407.
  • 53
    Cody J, Daly C, Campbell M, et al. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev. 2005;(3):CD003895.
  • 54
    Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005;(3):CD003266.
  • 55
    Jones M, Ibels L, Schenkel B, et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65(3):757767.
  • 56
    Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49(7):753762.
  • 57
    Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288(17):21442150.
  • 58
    Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150(4):707715.